# A Study of Orally Administered Pimodivir in Adult Participants With Hepatic Impairment

> **NCT03816631** · PHASE1 · COMPLETED · sponsor: **Janssen-Cilag International NV** · enrollment: 42 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** Pimodivir

## Key facts

- **NCT ID:** NCT03816631
- **Lead sponsor:** Janssen-Cilag International NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-28
- **Primary completion:** 2020-04-27
- **Final completion:** 2020-04-27
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03816631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03816631, "A Study of Orally Administered Pimodivir in Adult Participants With Hepatic Impairment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03816631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*